LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 142

Search options

  1. Article ; Online: Clinical significance of Janus Kinase inhibitor selectivity.

    Choy, Ernest H

    Rheumatology (Oxford, England)

    2019  Volume 58, Issue 6, Page(s) 1122

    Language English
    Publishing date 2019-01-30
    Publishing country England
    Document type Journal Article ; Published Erratum
    ZDB-ID 1464822-2
    ISSN 1462-0332 ; 1462-0324
    ISSN (online) 1462-0332
    ISSN 1462-0324
    DOI 10.1093/rheumatology/kez002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 240: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 497: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Using biologics safely.

    Choy, Ernest H

    Rheumatology (Oxford, England)

    2019  Volume 58, Issue 9, Page(s) 1515–1516

    MeSH term(s) Antirheumatic Agents ; Arthritis ; Biological Products ; Ethnic Groups ; Humans ; Rheumatology
    Chemical Substances Antirheumatic Agents ; Biological Products
    Language English
    Publishing date 2019-04-15
    Publishing country England
    Document type Editorial ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 1464822-2
    ISSN 1462-0332 ; 1462-0324
    ISSN (online) 1462-0332
    ISSN 1462-0324
    DOI 10.1093/rheumatology/kez129
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 240: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 497: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis.

    Choy, Ernest H

    Rheumatology (Oxford, England)

    2019  Volume 58, Issue Suppl 5, Page(s) v51–v55

    Abstract: Fatigue is a common and debilitating symptom in patients with RA. Since 2007, fatigue has been included as one of the core outcome measures in RA. Clinical trials of biologic DMARDs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) have included fatigue ...

    Abstract Fatigue is a common and debilitating symptom in patients with RA. Since 2007, fatigue has been included as one of the core outcome measures in RA. Clinical trials of biologic DMARDs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) have included fatigue as a secondary endpoint. A Cochrane review in 2016 concluded that the bDMARDs have a moderate effect on improving fatigue in RA. More recent clinical trials of the new biologic agent sarilumab and the Janus kinase inhibitors tofacitinib and baricitinib showed similar benefits. It remains unclear whether the effect of bDMARDs and tsDMARDs on fatigue is mediated by direct effects or through a reduction in inflammation. As fatigue was a secondary endpoint, many analyses did not adjust for potential confounding factors, including pain, mood and anaemia, which is a significant limitation.
    MeSH term(s) Antibodies, Monoclonal, Humanized/therapeutic use ; Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/complications ; Arthritis, Rheumatoid/drug therapy ; Azetidines/therapeutic use ; Biological Products/therapeutic use ; Fatigue/drug therapy ; Fatigue/etiology ; Humans ; Piperidines/therapeutic use ; Pyrimidines/therapeutic use ; Pyrroles/therapeutic use ; Sulfonamides/therapeutic use
    Chemical Substances Antibodies, Monoclonal, Humanized ; Antirheumatic Agents ; Azetidines ; Biological Products ; Piperidines ; Pyrimidines ; Pyrroles ; Sulfonamides ; tofacitinib (87LA6FU830) ; baricitinib (ISP4442I3Y) ; sarilumab (NU90V55F8I)
    Language English
    Publishing date 2019-11-04
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Systematic Review
    ZDB-ID 1464822-2
    ISSN 1462-0332 ; 1462-0324
    ISSN (online) 1462-0332
    ISSN 1462-0324
    DOI 10.1093/rheumatology/kez389
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 240: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 497: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Rheumatologists at a crossroads: blocking tumour necrosis factor or interleukin 6 in disease-modifying anti-rheumatic drug inadequate responder patients with rheumatoid arthritis.

    Quartuccio, Luca / Choy, Ernest H

    Rheumatology (Oxford, England)

    2021  Volume 60, Issue 11, Page(s) 4953–4955

    MeSH term(s) Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/drug therapy ; Humans ; Interleukin-6 ; Rheumatologists ; Tumor Necrosis Factor-alpha
    Chemical Substances Antirheumatic Agents ; Interleukin-6 ; Tumor Necrosis Factor-alpha
    Language English
    Publishing date 2021-05-11
    Publishing country England
    Document type Editorial ; Comment
    ZDB-ID 1464822-2
    ISSN 1462-0332 ; 1462-0324
    ISSN (online) 1462-0332
    ISSN 1462-0324
    DOI 10.1093/rheumatology/keab425
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 240: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 497: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Clinical significance of Janus Kinase inhibitor selectivity.

    Choy, Ernest H

    Rheumatology (Oxford, England)

    2018  Volume 58, Issue 6, Page(s) 953–962

    Abstract: Cytokines are key drivers of inflammation in RA, and anti-cytokine therapy has improved the outcome of RA. Janus Kinases (JAK) are intracellular tyrosine kinases linked to intracellular domains of many cytokine receptors. There are four JAK isoforms: ... ...

    Abstract Cytokines are key drivers of inflammation in RA, and anti-cytokine therapy has improved the outcome of RA. Janus Kinases (JAK) are intracellular tyrosine kinases linked to intracellular domains of many cytokine receptors. There are four JAK isoforms: JAK1, JAK2, JAK3 and TYK2. Different cytokine receptor families utilize specific JAK isoforms for signal transduction. Phosphorylation of JAK when cytokine binds to its cognate receptor leads to phosphorylation of other intracellular molecules that eventually leads to gene transcription. Oral JAK inhibitors (JAKi) have been developed as anti-cytokine therapy in RA. Two JAKi, tofacitinib and baricitinib, have been approved recently for the treatment of RA, and many JAKi are currently in development. JAKi inhibit JAK isoforms with different selectivity. This review discusses the efficacy and safety of JAKi in RA, in particular the potential clinical significance of JAKi selectivity.
    MeSH term(s) Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/drug therapy ; Azetidines/therapeutic use ; Humans ; Inflammation/drug therapy ; Janus Kinase Inhibitors/therapeutic use ; Piperidines/therapeutic use ; Pyrimidines/therapeutic use ; Pyrroles/therapeutic use ; Sulfonamides/therapeutic use
    Chemical Substances Antirheumatic Agents ; Azetidines ; Janus Kinase Inhibitors ; Piperidines ; Pyrimidines ; Pyrroles ; Sulfonamides ; tofacitinib (87LA6FU830) ; baricitinib (ISP4442I3Y)
    Language English
    Publishing date 2018-12-03
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 1464822-2
    ISSN 1462-0332 ; 1462-0324
    ISSN (online) 1462-0332
    ISSN 1462-0324
    DOI 10.1093/rheumatology/key339
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 240: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 497: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: C-reactive protein and implications in rheumatoid arthritis and associated comorbidities.

    Pope, Janet E / Choy, Ernest H

    Seminars in arthritis and rheumatism

    2020  Volume 51, Issue 1, Page(s) 219–229

    Abstract: C-reactive protein (CRP) is routinely assessed as a marker of systemic inflammation in rheumatoid arthritis (RA). However, it is also an immune regulator that plays an important role in inflammatory pathways associated with RA and promotes atherogenic ... ...

    Abstract C-reactive protein (CRP) is routinely assessed as a marker of systemic inflammation in rheumatoid arthritis (RA). However, it is also an immune regulator that plays an important role in inflammatory pathways associated with RA and promotes atherogenic effects. Comorbidities linked to systemic inflammation are common in RA, and CRP has been associated with the risk for cardiovascular disease, diabetes, metabolic syndrome, pulmonary diseases, and depression. The relationship between systemic inflammation, CRP, and comorbidities in RA is complex, and it is challenging to determine how changing CRP levels may affect the risk or progression of these comorbidities. We review the biological role of CRP in RA and its implications for disease activity and treatment response. We also discuss the impact of treatment on CRP levels and whether reducing systemic inflammation and inhibiting CRP-mediated inflammatory pathways may have an impact on conditions commonly comorbid with RA.
    MeSH term(s) Arthritis, Rheumatoid/epidemiology ; Biomarkers ; C-Reactive Protein/analysis ; Cardiovascular Diseases/epidemiology ; Humans ; Inflammation
    Chemical Substances Biomarkers ; C-Reactive Protein (9007-41-4)
    Language English
    Publishing date 2020-12-17
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 120247-9
    ISSN 1532-866X ; 0049-0172
    ISSN (online) 1532-866X
    ISSN 0049-0172
    DOI 10.1016/j.semarthrit.2020.11.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 790: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Fatigue in rheumatoid arthritis.

    Choy, Ernest H / Dures, Emma

    Rheumatology (Oxford, England)

    2019  Volume 58, Issue Suppl 5, Page(s) v1–v2

    MeSH term(s) Arthritis, Rheumatoid/complications ; Arthritis, Rheumatoid/rehabilitation ; Fatigue/etiology ; Fatigue/rehabilitation ; Humans ; Quality of Life ; Self-Management/methods ; Severity of Illness Index
    Language English
    Publishing date 2019-11-04
    Publishing country England
    Document type Editorial ; Research Support, Non-U.S. Gov't
    ZDB-ID 1464822-2
    ISSN 1462-0332 ; 1462-0324
    ISSN (online) 1462-0332
    ISSN 1462-0324
    DOI 10.1093/rheumatology/kez314
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 240: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 497: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Current treatments to counter sleep dysfunction as a pathogenic stimulus of fibromyalgia.

    Choy, Ernest H

    Pain management

    2016  Volume 6, Issue 4, Page(s) 339–346

    Abstract: Fibromyalgia is characterized by chronic widespread pain, fatigue and nonrestorative sleep. Polysomnography showed reduced short-wave sleep and abnormal alpha rhythms during nonrapid eye movement sleep in patients with fibromyalgia. However, sleep ... ...

    Abstract Fibromyalgia is characterized by chronic widespread pain, fatigue and nonrestorative sleep. Polysomnography showed reduced short-wave sleep and abnormal alpha rhythms during nonrapid eye movement sleep in patients with fibromyalgia. However, sleep dysfunction might be pathogenic in fibromyalgia since myalgia and fatigue could be induced in healthy individuals by disrupting sleep. Poor sleep quality was a major risk factor for the subsequent development of chronic widespread pain in healthy pain-free individuals. Sleep disruption leads to impairment of the descending pain inhibition pathways. Aside from good sleep, hygiene, exercise can promote sleep. Among currently available pharmacological treatments, evidence suggests amitriptyline and pregabalin can improve sleep in fibromyalgia.
    MeSH term(s) Fatigue/etiology ; Female ; Fibromyalgia/complications ; Fibromyalgia/physiopathology ; Humans ; Male ; Pain/etiology ; Pain Management ; Randomized Controlled Trials as Topic ; Sleep Wake Disorders/etiology ; Sleep Wake Disorders/physiopathology ; Sleep Wake Disorders/therapy
    Language English
    Publishing date 2016-05
    Publishing country England
    Document type Journal Article
    ISSN 1758-1877
    ISSN (online) 1758-1877
    DOI 10.2217/pmt-2016-0009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  9. Article ; Online: Harnessing CD8

    Ceeraz, Sabrina / Thompson, Charlotte R / Beatson, Richard / Choy, Ernest H

    Cells

    2021  Volume 10, Issue 11

    Abstract: T regulatory cell therapy presents a novel therapeutic strategy for patients with autoimmune diseases or who are undergoing transplantation. At present, the ... ...

    Abstract T regulatory cell therapy presents a novel therapeutic strategy for patients with autoimmune diseases or who are undergoing transplantation. At present, the CD4
    MeSH term(s) Animals ; Autoimmune Diseases/immunology ; Autoimmune Diseases/therapy ; CD28 Antigens/metabolism ; CD8-Positive T-Lymphocytes/immunology ; Humans ; Immunosuppression Therapy ; Immunotherapy, Adoptive ; T-Lymphocytes, Regulatory/immunology
    Chemical Substances CD28 Antigens
    Language English
    Publishing date 2021-11-01
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2661518-6
    ISSN 2073-4409 ; 2073-4409
    ISSN (online) 2073-4409
    ISSN 2073-4409
    DOI 10.3390/cells10112973
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Transforming clinical trials in rheumatology: towards patient-centric precision medicine.

    Pitzalis, Costantino / Choy, Ernest H S / Buch, Maya H

    Nature reviews. Rheumatology

    2020  Volume 16, Issue 10, Page(s) 590–599

    Abstract: Despite the success of targeted therapies in the treatment of inflammatory arthritides, the lack of predictive biomarkers drives a 'trial and error' approach to treatment allocation, leading to variable and/or unsatisfactory responses. In-depth ... ...

    Abstract Despite the success of targeted therapies in the treatment of inflammatory arthritides, the lack of predictive biomarkers drives a 'trial and error' approach to treatment allocation, leading to variable and/or unsatisfactory responses. In-depth characterization of the synovial tissue in rheumatoid arthritis, as well as psoriatic arthritis and spondyloarthritis, is bringing new insights into the diverse cellular and molecular features of these diseases and their potential links with different clinical and treatment-response phenotypes. Such progress raises the tantalizing prospect of improving response rates by matching the use of specific agents to the cognate target pathways that might drive particular disease subtypes in specific patient groups. Innovative patient-centric, molecular pathology-driven clinical trial approaches are needed to achieve this goal. Whilst progress is clearly being made, it is important to emphasize that this field is still in its infancy and there are a number of potential barriers to realizing the premise of patient-centric clinical trials.
    MeSH term(s) Antirheumatic Agents/therapeutic use ; Arthritis, Psoriatic/immunology ; Arthritis, Psoriatic/therapy ; Arthritis, Rheumatoid/immunology ; Arthritis, Rheumatoid/therapy ; Biological Factors/therapeutic use ; Biomarkers/analysis ; Humans ; Patient-Centered Care/methods ; Precision Medicine/methods ; Randomized Controlled Trials as Topic ; Rheumatology/trends ; Safety ; Spondylarthritis/immunology ; Spondylarthritis/therapy ; Synovial Fluid/drug effects ; Synovial Fluid/metabolism ; Treatment Outcome
    Chemical Substances Antirheumatic Agents ; Biological Factors ; Biomarkers
    Language English
    Publishing date 2020-09-04
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2491532-4
    ISSN 1759-4804 ; 1759-4790
    ISSN (online) 1759-4804
    ISSN 1759-4790
    DOI 10.1038/s41584-020-0491-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6338: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top